Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics

  title={Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics},
  author={R. Scott Obach and Tim F. Ryder},
  journal={Drug Metabolism and Disposition},
  pages={1381 - 1391}
Ramelteon is a melatonin receptor agonist used as a treatment for insomnia. It is subject to a remarkably large drug-drug interaction (DDI) caused by fluvoxamine coadministration, resulting in a more than 100-fold increase in exposure. The objective of this study was to determine whether the DDI could be estimated using in vitro metabolism data. Ramelteon was shown to undergo hydroxylation in human liver microsomes to eight metabolites via six pathways. The main routes of metabolism included… 

Tables from this paper

Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2‐ and CYP3A4‐selective Inhibitors

The findings suggest that the intrinsic activities of CYPs 1A2 and 3A4 are unrelated to the response to CYP‐selective inhibitors and that assessment of the activities in vivo may not assist the prediction of drug–drug interactions.

Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice

An enzyme kinetic-based model is developed to enable more accurate prediction of the fate of new chemicals in humans and which can be validated in vivo using mice humanized for cytochrome P450–mediated metabolism.

Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants.

  • K. Iga
  • Biology
    Journal of pharmaceutical sciences
  • 2015
Despite large differences in AUCRs, CYP1A2 or CYP2C19 substrate-victimized DDIs resulted in equivalent inhibition constants and net enzymatic inhibitory activities calculated by eliminating hepatic availability increases for victims, suggesting the usefulness of a tube-based static method for DDI prediction.

Biosynthesis of Fluorinated Analogs of Drugs Using Human Cytochrome P450 Enzymes Followed by Deoxyfluorination and Quantitative Nuclear Magnetic Resonance Spectroscopy to Improve Metabolic Stability

A facile two-step method of inserting fluorine into metabolically labile sites of drug molecules is described that utilizes less than 1 mg of starting material and quantitative NMR spectroscopy to ascertain the structures and concentrations of products.

Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers

In insights into the interaction profiles of drugs poorly studied so far are provided and can help to identify and manage significant interactions in clinical practice.

Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products

Clinical studies are needed in order to determine the effects of other drugs on pharmacokinetics and pharmacodynamics of marijuana and cannabis products, with a significant increase in the USA due to the increasing number of states that allow medical and recreational use.

Sulfation of 6-hydroxymelatonin, N-acetylserotonin and 4-hydroxyramelteon by the human cytosolic sulfotransferases (SULTs)

Collectively, these results provided a molecular basis for the metabolism of 6-OH-Mel, NAS and 4- OH-Ram through sulfation.

Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

The results of this study suggest that inhibition of multiple clearance pathways in vivo is clinically relevant, and the risk of DDIs with object drugs may be best evaluated in studies using multi-P450 inhibitors.



Effects of Fluvoxamine on Lansoprazole Pharmacokinetics in Relation to CYP2C19 Genotypes

There is a significant difference in the fluvoxamine‐mediated percentage increase in the AUC0‐∞ of lansoprazole between CYP2C19 genotypes and the present study indicates that there are significant drug interactions between lansOPrazole and fluVoxamine in EMs.

Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants.

TCAs appear to have minimal potential for MBI of human liver microsomal CYP enzymes involved in drug metabolism, and HLM and recombinant CYP are not equivalent enzyme sources for evaluating the TDI associated with some drugs.

Effect of fluconazole on theophylline disposition in humans

The results indicate that fluconazole is a minor inhibitor of theophylline disposition compared with enoxacin, and they suggest that the inhibitory action of fluconAZole is selective for certain cytochrome P-450 isozymes, but not for the cyto chrome P-4501A involved in theophyLLine metabolism.

Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.

Assessment of theophylline metabolism indeed serves as a biomarker for CYP1A2, and in four subjects a marked induction was seen for all pharmacokinetic parameters, suggesting that the susceptibility to induction is more pronounced in some subjects.

Use of Isolated Hepatocyte Preparations for Cytochrome P450 Inhibition Studies: Comparison with Microsomes for Ki Determination

The data suggest that the hepatic accumulation of these inhibitors results from intracellular binding rather than the involvement of uptake transporters and indicate that microsomes and hepatocytes appear to be equivalent for determining the inhibitory potency of the six inhibitors investigated in the present study.

The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone

Fluvoxamine moderately increased plasma buspirone concentrations and decreased the production of the active 1-PP metabolite of buspir one, and this pharmacokinetic interaction was not associated with impairment of psychomotor performance and it is probably of limited clinical significance.

The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions

Findings support the conclusion that P450 in vitro inhibition data are valuable in designing clinical DDI study strategies and can be used to predict the magnitudes of DDI.


The effects on theophylline oxidative metabolism of 3 inhibitors of liver microsome activity — cimetidine, troleandomycin and ketoconazole — were investigated in 6 healthy volunteers and measurement of theophyLLine metabolite formation clearances might be a useful test to explore liver micro some oxidative function.